About ZemairaWhat is Alpha-1?Patient SupportPatient SupportFor Healthcare ProfessionalsPrescribing InformationImportant Safety InformationAlready Treating Your Alpha-1?Newly diagnosed with alpha-1?Diagnosed with Chronic Lung Disease?Receive Zemaira at no charge for up to 2 weeks.

My Steps for Healthy Living - Online Report Card

THIS PAGE IS FOR MY STEPS FOR HEALTHY LIVING REGISTRANTS ONLY. IF YOU ARE NOT CURRENTLY REGISTERED FOR THE PROGRAM, PLEASE DO SO BEFORE FILLING OUT THE REPORT CARD. REGISTER HERE.
Click here to download a printable copy of the Log Sheet.
Instructions for report card.

    Beginning of program:

  1. On Day 1, put on your pedometer as soon as you get up.
  2. At the end of the first day, record the number of steps you walked on your log sheet and on the My Steps For Healthy Living Report Card (See Below).

    3. Your goal is to increase the number of steps you take by 10% from the first day of the monthto the last day of the month. For example, if on March 1 you walk 2,000 steps, your goal is to walk 2,200 steps on March 31—an increase of 10%. If you are not able to increase your steps by 10% in a month, don’t worry—and don’t give up! Remember: You don’t have to walk fast or for long periods of time!

    End of month:

  3. At the end of the month, record your steps by completing the online My Steps for Healthy Living - Online Report Card listed below and click SUBMIT.
  4. Once your submission is processed, you will receive a motivational reward. It is our way of congratulating you for a job well done.
My Steps for Healthy Living Online Report Card
  • All fields marked with an asterisk(*) are required.
  •  
  •  
  •  
  •  
  •  

Important Safety Information

Alpha1-Proteinase Inhibitor (Human), Zemaira is indicated for chronic augmentation and maintenance therapy for adults with alpha1-proteinase inhibitor (A1-PI) deficiency and emphysema. Clinical data demonstrating the long-term effects of chronic augmentation therapy with Zemaira are not available.

Zemaira may not be appropriate for the following adult individuals as they may experience severe reactions, including anaphylaxis: individuals with a known hypersensitivity and/or history of anaphylaxis or severe systemic reaction to A1-PI products or their components, and individuals with selective IgA deficiencies who have known antibodies against IgA.

In clinical studies, the following treatment-related adverse reactions were reported in 1% of subjects: asthenia (fatigue), injection-site pain, dizziness, headache, paresthesia (tingling), and pruritus (itching).

Zemaira is derived from human plasma. The risk of transmission of infectious agents, including viruses and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent, cannot be completely eliminated.

Please see full prescribing information.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.